Gilead Sciences' (GILD) Antiviral Drug Remdesivir Flops in First trial - FT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Gilead Sciences (GILD) China Trial Results 'In Line with our Expectations' - RBC
April 23, 2020 1:40 PM EDTRBC Capital analyst Brian Abrahams weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
"If this is ultimately confirmed, this would be completely in line with our... More
Gilead Sciences (GILD) Remdesivir China Results 'Very Sobering' - Baird
April 23, 2020 1:34 PM EDTBaird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
Skorney commented, "This afternoon, an abstract leaked indicating that Gilead's remdesivir failed to provide a benefit... More
Gilead Sciences (GILD) Halted on LUDP
April 23, 2020 12:46 PM EDTGilead Sciences (NASDAQ: GILD) Halted on LUDP
... More